Clinical trial
Prospective Single-arm, Exploratory, Multicenter Phase II Clinical Study of Camrelizumab Combined With Chemoradiotherapy in the Treatment of Advanced First-line Esophageal Phosphorous Carcinoma
NCT05624099 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Single-arm, Exploratory, Multicenter Phase II Clinical Study of Camrelizumab Combined With Chemoradiotherapy in the Treatment of Advanced First-line Esophageal Phosphorous Carcinoma
- Lead sponsor
- Fujian Cancer Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 1, 2023
- Completion date
- December 31, 2027
- Enrollment
- 75 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.